Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Lung Cancer

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 302 articles:
HTML format



Single Articles


    November 2022
  1. GALINDO-UTRERO A, San-Roman-Montero JM, Gil-Prieto R, Gil-de-Miguel A, et al
    Trends in hospitalization and in-hospital mortality rates among patients with lung cancer in Spain between 2010 and 2020.
    BMC Cancer. 2022;22:1199.
    PubMed     Abstract available


  2. SINN K, Mosleh B, Grusch M, Klepetko W, et al
    Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection.
    BMC Cancer. 2022;22:1197.
    PubMed     Abstract available


  3. XU K, Cai J, Xing J, Li X, et al
    Broad-spectrum antibiotics associated gut microbiome disturbance impairs T cell immunity and promotes lung cancer metastasis: a retrospective study.
    BMC Cancer. 2022;22:1182.
    PubMed     Abstract available


  4. KIM N, Jeong D, Jo A, Eum HH, et al
    Prescreening of tumor samples for tumor-centric transcriptome analyses of lung adenocarcinoma.
    BMC Cancer. 2022;22:1186.
    PubMed     Abstract available


  5. GENG T, Li M, Chen R, Yang S, et al
    Impact of GTF2H1 and RAD54L2 polymorphisms on the risk of lung cancer in the Chinese Han population.
    BMC Cancer. 2022;22:1181.
    PubMed     Abstract available


  6. LIU Y, Gao Y, Wang Y, Zhao C, et al
    A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice.
    BMC Cancer. 2022;22:1175.
    PubMed     Abstract available


  7. SATO K, Akamatsu H, Koh Y, Ogawa K, et al
    Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
    BMC Cancer. 2022;22:1148.
    PubMed     Abstract available


  8. JIANG L, Sun YQ, Brumpton BM, Langhammer A, et al
    Body mass index and incidence of lung cancer in the HUNT study: using observational and Mendelian randomization approaches.
    BMC Cancer. 2022;22:1152.
    PubMed     Abstract available


  9. PAN J, Huang Z, Lin H, Cheng W, et al
    M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma.
    BMC Cancer. 2022;22:1132.
    PubMed     Abstract available


  10. ASAO T, Watanabe S, Tanaka T, Morita S, et al
    A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.
    BMC Cancer. 2022;22:1135.
    PubMed     Abstract available


  11. KIM S, Koh J, Song SG, Yim J, et al
    High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration.
    BMC Cancer. 2022;22:1120.
    PubMed     Abstract available


  12. ZHANG R, Wei Y, Shi F, Ren J, et al
    The diagnostic and prognostic value of radiomics and deep learning technologies for patients with solid pulmonary nodules in chest CT images.
    BMC Cancer. 2022;22:1118.
    PubMed     Abstract available


    October 2022
  13. JIANG Y, Han R, Su J, Fan X, et al
    Trends and predictions of lung cancer incidence in Jiangsu Province, China, 2009-2030: a bayesian age-period-cohort modelling study.
    BMC Cancer. 2022;22:1110.
    PubMed     Abstract available


  14. QU L, Tian Y, Wang F, Li Z, et al
    NOVA1 promotes NSCLC proliferation and invasion by activating Wnt/beta-catenin signaling.
    BMC Cancer. 2022;22:1091.
    PubMed     Abstract available


  15. ZHANG HY, Xie HL, Ruan GT, Zhang Q, et al
    Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.
    BMC Cancer. 2022;22:1080.
    PubMed     Abstract available


  16. LIAO K, Wang T, Coomber-Moore J, Wong DC, et al
    Prognostic value of patient-reported outcome measures (PROMs) in adults with non-small cell Lung Cancer: a scoping review.
    BMC Cancer. 2022;22:1076.
    PubMed     Abstract available


  17. KOJIMA K, Imai S, Samejima H, Fujiwara A, et al
    PIK3CA mutations associated with a poor postoperative prognosis in patients with pulmonary pleomorphic carcinoma: a retrospective cohort study.
    BMC Cancer. 2022;22:1066.
    PubMed     Abstract available


  18. JI J, Sundquist J, Sundquist K, Zheng G, et al
    Familial risk associated with lung cancer as a second primary malignancy in first-degree relatives.
    BMC Cancer. 2022;22:1057.
    PubMed     Abstract available


  19. KUROKAWA K, Mitsuishi Y, Shimada N, Kawakami Y, et al
    Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study.
    BMC Cancer. 2022;22:1047.
    PubMed     Abstract available


  20. FUJII H, Nagakura H, Kobayashi N, Kubo S, et al
    Liquid biopsy for detecting epidermal growth factor receptor mutation among patients with non-small cell lung cancer treated with afatinib: a multicenter prospective study.
    BMC Cancer. 2022;22:1035.
    PubMed     Abstract available


    September 2022
  21. HUA T, Gao Y, Zhang R, Wei Y, et al
    Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    BMC Cancer. 2022;22:1022.
    PubMed     Abstract available


  22. WU H, Ji H, Yang W, Zhang M, et al
    Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
    BMC Cancer. 2022;22:1020.
    PubMed     Abstract available


  23. CHEN Z, Zhou L, Zhao M, Cao K, et al
    Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
    BMC Cancer. 2022;22:1010.
    PubMed     Abstract available


  24. BOZORGMEHR F, Christopoulos P, Chung I, Cvetkovic J, et al
    Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
    BMC Cancer. 2022;22:1011.
    PubMed     Abstract available


  25. QIN H, Ke J, Dong S, Li H, et al
    Effect of thoracic radiotherapy dose on the prognosis of advanced lung adenocarcinoma harboring EGFR mutations.
    BMC Cancer. 2022;22:1012.
    PubMed     Abstract available


  26. RACZKOWSKI L, Pasnik I, Kukielka M, Nicos M, et al
    Deep learning-based tumor microenvironment segmentation is predictive of tumor mutations and patient survival in non-small-cell lung cancer.
    BMC Cancer. 2022;22:1001.
    PubMed     Abstract available


  27. HOANG NTD, Hassan G, Suehiro T, Mine Y, et al
    BMP and activin membrane-bound inhibitor regulate connective tissue growth factor controlling mesothelioma cell proliferation.
    BMC Cancer. 2022;22:984.
    PubMed     Abstract available


  28. ZHOU L, Zhang Y, Chen W, Niu N, et al
    Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort.
    BMC Cancer. 2022;22:980.
    PubMed     Abstract available


  29. MIYAZAKI K, Shiba A, Ikeda T, Higashi Y, et al
    Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study.
    BMC Cancer. 2022;22:977.
    PubMed     Abstract available


  30. ISAKA T, Ito H, Yokose T, Saito H, et al
    Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
    BMC Cancer. 2022;22:966.
    PubMed     Abstract available


  31. SHIRAISHI Y, Kishimoto J, Shimose T, Toi Y, et al
    Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial.
    BMC Cancer. 2022;22:964.
    PubMed     Abstract available


  32. SAIFON W, Sensorn I, Trachu N, Oranratnachai S, et al
    Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer.
    BMC Cancer. 2022;22:963.
    PubMed     Abstract available


  33. JIANG Y, Xiong Z, Zhao W, Tian D, et al
    Pathological components and CT imaging analysis of the area adjacent pleura within the pure ground-glass nodules with pleural deformation in invasive lung adenocarcinoma.
    BMC Cancer. 2022;22:958.
    PubMed     Abstract available


  34. ZHANG Y, Song L, Zeng L, Xiong Y, et al
    Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study.
    BMC Cancer. 2022;22:952.
    PubMed     Abstract available


  35. MA Y, Li J, Xu X, Zhang Y, et al
    The CT delta-radiomics based machine learning approach in evaluating multiple primary lung adenocarcinoma.
    BMC Cancer. 2022;22:949.
    PubMed     Abstract available


    August 2022
  36. TREMBECKI L, Sztuder A, Debicka I, Matkowski R, et al
    The pilot project of the National Cancer Network in Poland: Assessment of the functioning of the National Cancer Network and results from quality indicators for lung cancer (2019-2021).
    BMC Cancer. 2022;22:939.
    PubMed     Abstract available


  37. XU H, Qi Z, Zhao Q, Xue J, et al
    Lentinan enhances the antitumor effects of Delta-like 1 via neutrophils.
    BMC Cancer. 2022;22:918.
    PubMed     Abstract available


  38. MENG Y, Gao J, Wu C, Xie M, et al
    The prognosis of different types of pleural tags based on radiologic-pathologic comparison.
    BMC Cancer. 2022;22:919.
    PubMed     Abstract available


  39. CHE H, Xiong Q, Ma J, Chen S, et al
    Association of Helicobacter pylori infection with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    BMC Cancer. 2022;22:904.
    PubMed     Abstract available


  40. SUN J, Fang F, Olen O, Song M, et al
    Normal gastrointestinal mucosa at biopsy and subsequent cancer risk: nationwide population-based, sibling-controlled cohort study.
    BMC Cancer. 2022;22:890.
    PubMed     Abstract available


  41. FAN Y, Dong Y, Sun X, Wang H, et al
    Development and validation of MRI-based radiomics signatures as new markers for preoperative assessment of EGFR mutation and subtypes from bone metastases.
    BMC Cancer. 2022;22:889.
    PubMed     Abstract available


  42. ITO H, Date H, Shintani Y, Miyaoka E, et al
    The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010.
    BMC Cancer. 2022;22:875.
    PubMed     Abstract available


  43. JIAO Z, Feng X, Cui Y, Wang L, et al
    Expression characteristic, immune signature, and prognosis value of EFNA family identified by multi-omics integrative analysis in pan-cancer.
    BMC Cancer. 2022;22:871.
    PubMed     Abstract available


  44. WANG X, Huang Z, Li L, Wang G, et al
    DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
    BMC Cancer. 2022;22:866.
    PubMed     Abstract available


  45. MITCHELL H, Alford BS, O'Hare S, O'Callaghan E, et al
    Impact of the COVID-19 pandemic on emergency hospital cancer admissions in a UK region.
    BMC Cancer. 2022;22:850.
    PubMed     Abstract available


    July 2022
  46. ZHANG G, Fan J, Yu Z, Chai Y, et al
    Video-assisted thoracoscopic treatment as two-day surgery for lung neoplasms: a propensity-matched analysis.
    BMC Cancer. 2022;22:832.
    PubMed     Abstract available


  47. KANG Y, Gan Y, Jiang Y, You J, et al
    Cancer-testis antigen KK-LC-1 is a potential biomarker associated with immune cell infiltration in lung adenocarcinoma.
    BMC Cancer. 2022;22:834.
    PubMed     Abstract available


  48. AKGUL S, Chan BA, Manders PM
    Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice.
    BMC Cancer. 2022;22:829.
    PubMed     Abstract available


  49. LI B, Jiang C, Xu Y, Fan X, et al
    Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancer.
    BMC Cancer. 2022;22:828.
    PubMed     Abstract available


  50. LIU Z, Diao Y, Li X
    Body mass index and serum markers associated with progression-free survival in lung cancer patients treated with immune checkpoint inhibitors.
    BMC Cancer. 2022;22:824.
    PubMed     Abstract available


  51. LI L, Chen Y, Liao W, Yu Q, et al
    Associations of IFT20 and GM130 protein expressions with clinicopathological features and survival of patients with lung adenocarcinoma.
    BMC Cancer. 2022;22:809.
    PubMed     Abstract available


  52. WANG Q, Wang S, Sun Z, Cao M, et al
    Evaluation of log odds of positive lymph nodes in predicting the survival of patients with non-small cell lung cancer treated with neoadjuvant therapy and surgery: a SEER cohort-based study.
    BMC Cancer. 2022;22:801.
    PubMed     Abstract available


  53. ZHAO J, Barta JA, McIntire R, Shusted C, et al
    Racial difference in BMI and lung cancer diagnosis: analysis of the National Lung Screening Trial.
    BMC Cancer. 2022;22:797.
    PubMed     Abstract available


  54. MATSUMOTO Y, Kawaguchi T, Watanabe M, Isa SI, et al
    Prognostic impact of pretreatment T790M mutation on outcomes for patients with resected, EGFR-mutated, non-small cell lung cancer.
    BMC Cancer. 2022;22:775.
    PubMed     Abstract available


  55. LING Q, Wu S, Liao X, Liu C, et al
    Anesthetic propofol enhances cisplatin-sensitivity of non-small cell lung cancer cells through N6-methyladenosine-dependently regulating the miR-486-5p/RAP1-NF-kappaB axis.
    BMC Cancer. 2022;22:765.
    PubMed     Abstract available


  56. FENG H, Cao B, Peng X, Wei Q, et al
    Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer.
    BMC Cancer. 2022;22:764.
    PubMed     Abstract available


  57. SUN M, Ji H, Xu N, Jiang P, et al
    Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
    BMC Cancer. 2022;22:762.
    PubMed     Abstract available


  58. FAIRLEY JA, Cheetham MH, Patton SJ, Rouleau E, et al
    Results of a worldwide external quality assessment of cfDNA testing in lung Cancer.
    BMC Cancer. 2022;22:759.
    PubMed     Abstract available


  59. FANG DD, Tao R, Wang G, Li Y, et al
    Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
    BMC Cancer. 2022;22:752.
    PubMed     Abstract available


  60. OTSUKA T, Nishida S, Shibahara T, Temizoz B, et al
    CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study.
    BMC Cancer. 2022;22:744.
    PubMed     Abstract available


  61. WANG Y, Fang C, Chen R, Yuan S, et al
    rhG-CSF is associated with an increased risk of metastasis in NSCLC patients following postoperative chemotherapy.
    BMC Cancer. 2022;22:741.
    PubMed     Abstract available


  62. MEI J, Jiang G, Chen Y, Xu Y, et al
    HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC.
    BMC Cancer. 2022;22:738.
    PubMed     Abstract available


  63. DUFRAING K, Van Casteren K, Breyne J, D'Haene N, et al
    Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders.
    BMC Cancer. 2022;22:736.
    PubMed     Abstract available


  64. PROVENCIO M, Cobo M, Rodriguez-Abreu D, Calvo V, et al
    Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics.
    BMC Cancer. 2022;22:732.
    PubMed     Abstract available


    June 2022
  65. LIU L, Liu J, Deng X, Tu L, et al
    A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma.
    BMC Cancer. 2022;22:715.
    PubMed     Abstract available


  66. ZHOU W, Zhang W
    A novel pyroptosis-related lncRNA prognostic signature associated with the immune microenvironment in lung squamous cell carcinoma.
    BMC Cancer. 2022;22:694.
    PubMed     Abstract available


  67. MOORE A, Bennett B, Taylor-Stokes G, McDonald L, et al
    Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe.
    BMC Cancer. 2022;22:693.
    PubMed     Abstract available


  68. ZHANG K, Wang K, Zhang C, Teng X, et al
    Exploring the potential mechanism of emetine against coronavirus disease 2019 combined with lung adenocarcinoma: bioinformatics and molecular simulation analyses.
    BMC Cancer. 2022;22:687.
    PubMed     Abstract available


  69. YUAN J, Sun Y, Wang K, Wang Z, et al
    Development and validation of reassigned CEA, CYFRA21-1 and NSE-based models for lung cancer diagnosis and prognosis prediction.
    BMC Cancer. 2022;22:686.
    PubMed     Abstract available


  70. HAO X, Zhang J, Chen G, Cao W, et al
    Aberrant expression of GSTM5 in lung adenocarcinoma is associated with DNA hypermethylation and poor prognosis.
    BMC Cancer. 2022;22:685.
    PubMed     Abstract available


  71. QIU L, Xu Y, Xu H, Yu B, et al
    The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.
    BMC Cancer. 2022;22:681.
    PubMed     Abstract available


  72. ZHANG X, Wang D, Sun T, Li W, et al
    Advanced lung cancer inflammation index (ALI) predicts prognosis of patients with gastric cancer after surgical resection.
    BMC Cancer. 2022;22:684.
    PubMed     Abstract available


  73. HUANG WJ, Wang GY, Liu ZY, Zhang ML, et al
    Preoperative PDW levels predict pulmonary metastasis in patients with hepatocellular carcinoma.
    BMC Cancer. 2022;22:683.
    PubMed     Abstract available


  74. ZHENG Q, Min S, Zhou Y
    A network meta-analysis for efficacies and toxicities of different concurrent chemoradiotherapy regimens in the treatment of locally advanced non-small cell lung cancer.
    BMC Cancer. 2022;22:674.
    PubMed     Abstract available


  75. GEN S, Tanaka I, Morise M, Koyama J, et al
    Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    BMC Cancer. 2022;22:654.
    PubMed     Abstract available


  76. DENG S, Jiang Z, Cao Y, Gu J, et al
    Development and validation of a prognostic scoring system for patients with colorectal cancer hepato-pulmonary metastasis: a retrospective study.
    BMC Cancer. 2022;22:643.
    PubMed     Abstract available


  77. CALVET L, Dos-Santos O, Spanakis E, Jean-Baptiste V, et al
    YAP1 is essential for malignant mesothelioma tumor maintenance.
    BMC Cancer. 2022;22:639.
    PubMed     Abstract available


  78. JIANG J, Lu Y, Zhang F, Pan T, et al
    Semaphorin 4B promotes tumor progression and associates with immune infiltrates in lung adenocarcinoma.
    BMC Cancer. 2022;22:632.
    PubMed     Abstract available


  79. WANG Y, Song W, Zhou S, Chang S, et al
    The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
    BMC Cancer. 2022;22:618.
    PubMed     Abstract available


  80. NOKIHARA H, Ogino H, Mitsuhashi A, Kondo K, et al
    Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion.
    BMC Cancer. 2022;22:597.
    PubMed     Abstract available


    May 2022
  81. YANG J, Luo G, Li C, Zhao Z, et al
    Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
    BMC Cancer. 2022;22:589.
    PubMed     Abstract available


  82. TSE LA, Wang F, Wong MC, Au JS, et al
    Risk assessment and prediction for lung cancer among Hong Kong Chinese men.
    BMC Cancer. 2022;22:585.
    PubMed     Abstract available


  83. JIN Y, Lin C, Shi X, He Q, et al
    Impact of clinical and molecular features on efficacy and outcome of patients with non-small cell lung cancer receiving second-line osimertinib.
    BMC Cancer. 2022;22:586.
    PubMed     Abstract available


  84. LEIBOWITZ BD, Dougherty BV, Bell JSK, Kapilivsky J, et al
    Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort.
    BMC Cancer. 2022;22:587.
    PubMed     Abstract available


  85. YANG H, Wen L, Pan Y, Shan C, et al
    Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    BMC Cancer. 2022;22:580.
    PubMed     Abstract available


  86. GU X, Shi Z, Shao L, Zhang Y, et al
    Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2022;22:576.
    PubMed     Abstract available


  87. SHENG H, Hao Z, Zhu L, Zeng Y, et al
    Construction and validation of a two-gene signature based on SUMOylation regulatory genes in non-small cell lung cancer patients.
    BMC Cancer. 2022;22:572.
    PubMed     Abstract available


  88. CHEN CL, Wang ST, Liao WC, Chen CH, et al
    When to add anti-angiogenesis drugs to EGFR-mutated metastatic non-small cell lung cancer patients: a real-world study from Taiwan.
    BMC Cancer. 2022;22:571.
    PubMed     Abstract available


  89. TANG Y, Luo J, Zhou Y, Zang H, et al
    Overexpressed p-S6 associates with lymph node metastasis and predicts poor prognosis in non-small cell lung cancer.
    BMC Cancer. 2022;22:564.
    PubMed     Abstract available


  90. CAMINA N, McWilliams TL, McKeon TP, Penning TM, et al
    Identification of spatio-temporal clusters of lung cancer cases in Pennsylvania, USA: 2010-2017.
    BMC Cancer. 2022;22:555.
    PubMed     Abstract available


  91. KIM J, You HJ, Youn C
    SCARA3 inhibits cell proliferation and EMT through AKT signaling pathway in lung cancer.
    BMC Cancer. 2022;22:552.
    PubMed     Abstract available


  92. UCHIDA Y, Kinose D, Nagatani Y, Tanaka-Mizuno S, et al
    Risk factors for pneumonitis in advanced extrapulmonary cancer patients treated with immune checkpoint inhibitors.
    BMC Cancer. 2022;22:551.
    PubMed     Abstract available


  93. WANG C, Zhu S, Miao C, Wang Y, et al
    Safety and efficacy of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy for small-cell lung cancer: a retrospective, cohort-controlled trial.
    BMC Cancer. 2022;22:542.
    PubMed     Abstract available


  94. SONG X, Xie Y, Zhu Y, Lou Y, et al
    Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis.
    BMC Cancer. 2022;22:541.
    PubMed     Abstract available


  95. EBERST G, Vernerey D, Laheurte C, Meurisse A, et al
    Prognostic value of CD4+ T lymphopenia in non-small cell lung Cancer.
    BMC Cancer. 2022;22:529.
    PubMed     Abstract available


  96. TANG S, Ni J, Chen B, Sun F, et al
    PAFAH1B3 predicts poor prognosis and promotes progression in lung adenocarcinoma.
    BMC Cancer. 2022;22:525.
    PubMed     Abstract available


  97. XU Z, Liu C, Zhu Y, Zou Z, et al
    Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.
    BMC Cancer. 2022;22:514.
    PubMed     Abstract available


  98. TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
    A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study.
    BMC Cancer. 2022;22:503.
    PubMed     Abstract available


  99. XU J, Zhi X, Xie L, Sun X, et al
    Long-term outcome and relapse patterns in Ewing sarcoma patients with extensive lung/pleural metastases after a complete response to systemic therapy.
    BMC Cancer. 2022;22:500.
    PubMed     Abstract available


  100. DU R, Yang H, Zhou H, Ma L, et al
    The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy.
    BMC Cancer. 2022;22:491.
    PubMed     Abstract available


    April 2022
  101. RODRIGUES A, Chauhan J, Sagkriotis A, Aasaithambi S, et al
    Understanding the lived experience of lung cancer: a European social media listening study.
    BMC Cancer. 2022;22:475.
    PubMed     Abstract available


  102. VIRGILSEN LF, Vedsted P, Falborg AZ, Pedersen AF, et al
    Routes to cancer diagnosis for patients with pre-existing psychiatric disorders: a nationwide register-based cohort study.
    BMC Cancer. 2022;22:472.
    PubMed     Abstract available


  103. KAGIMOTO A, Mimura T, Kamigaichi A, Yamashita Y, et al
    Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings.
    BMC Cancer. 2022;22:469.
    PubMed     Abstract available


  104. DHALIWAL I, Kassirian S, Mitchell MA, Qiabi M, et al
    Endoscopic nodal staging in oligometastatic non-small cell lung cancer (NSCLC) being treated with stereotactic ablative radiotherapy (ENDO-SABR).
    BMC Cancer. 2022;22:468.
    PubMed     Abstract available


  105. HYLDGAARD C, Trolle C, Harders SMW, Engberg H, et al
    Increased use of diagnostic CT imaging increases the detection of stage IA lung cancer: pathways and patient characteristics.
    BMC Cancer. 2022;22:464.
    PubMed     Abstract available


  106. ZHOU W, Ma J, Meng L, Liu D, et al
    Deletion of TRIB3 disrupts the tumor progression induced by integrin alphavbeta3 in lung cancer.
    BMC Cancer. 2022;22:459.
    PubMed     Abstract available


  107. HAN KT, Chang J, Choi DW, Kim S, et al
    Association of institutional transition of cancer care with mortality in elderly patients with lung cancer: a retrospective cohort study using national claim data.
    BMC Cancer. 2022;22:452.
    PubMed     Abstract available


  108. JIANG R, Huang J, Sun X, Chu X, et al
    Construction of in vitro 3-D model for lung cancer-cell metastasis study.
    BMC Cancer. 2022;22:438.
    PubMed     Abstract available


  109. ZIOLKOWSKA B, Cybulska-Stopa B, Papantoniou D, Suwinski R, et al
    Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
    BMC Cancer. 2022;22:432.
    PubMed     Abstract available


  110. MATSUNAGA T, Saito H, Kuroda H, Osaki T, et al
    CA19-9 in combination with P-CRP as a predictive marker of immune-related adverse events in patients with recurrent or unresectable advanced gastric cancer treated with nivolumab.
    BMC Cancer. 2022;22:418.
    PubMed     Abstract available


  111. ZHANG X, Wu Z, Ma K
    SNCA correlates with immune infiltration and serves as a prognostic biomarker in lung adenocarcinoma.
    BMC Cancer. 2022;22:406.
    PubMed     Abstract available


  112. RANGANATH H, Jain AL, Smith JR, Ryder J, et al
    Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    BMC Cancer. 2022;22:407.
    PubMed     Abstract available


  113. ZHANG Y, Xiao P, Hu X
    LINC00511 enhances LUAD malignancy by upregulating GCNT3 via miR-195-5p.
    BMC Cancer. 2022;22:389.
    PubMed     Abstract available


  114. YANG H, Chen H, Zhang G, Li H, et al
    Diagnostic value of circulating genetically abnormal cells to support computed tomography for benign and malignant pulmonary nodules.
    BMC Cancer. 2022;22:382.
    PubMed     Abstract available


  115. YAMAMOTO T, Tsukita Y, Katagiri Y, Matsushita H, et al
    Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice.
    BMC Cancer. 2022;22:364.
    PubMed     Abstract available


    March 2022
  116. ZHU GL, Xu C, Yang KB, Tang SQ, et al
    Causal relationship between genetically predicted depression and cancer risk: a two-sample bi-directional mendelian randomization.
    BMC Cancer. 2022;22:353.
    PubMed     Abstract available


  117. MIYAWAKI E, Kenmotsu H, Shintani Y, Sekine I, et al
    Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study.
    BMC Cancer. 2022;22:342.
    PubMed     Abstract available


  118. ZHAO P, Zhen H, Zhao H, Zhao L, et al
    Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
    BMC Cancer. 2022;22:328.
    PubMed     Abstract available


  119. SHIMAMURA SS, Shukuya T, Asao T, Hayakawa D, et al
    Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer-is there a "tail plateau" in the survival curve of these patients?
    BMC Cancer. 2022;22:323.
    PubMed     Abstract available


  120. GUGGENBERGER J, Kenndoff S, Taugner J, Kasmann L, et al
    Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
    BMC Cancer. 2022;22:317.
    PubMed     Abstract available


  121. ZHANG Y, Wang W, Hu Q, Liang Z, et al
    Clinic and genetic similarity assessments of atypical carcinoid, neuroendocrine neoplasm with atypical carcinoid morphology and elevated mitotic count and large cell neuroendocrine carcinoma.
    BMC Cancer. 2022;22:321.
    PubMed     Abstract available


  122. YANG F, Sun Z, Wang D, Du T, et al
    MiR-106b-5p regulates esophageal squamous cell carcinoma progression by binding to HPGD.
    BMC Cancer. 2022;22:308.
    PubMed     Abstract available


  123. ZHANG W, Zhang Q, Che L, Xie Z, et al
    Using biological information to analyze potential miRNA-mRNA regulatory networks in the plasma of patients with non-small cell lung cancer.
    BMC Cancer. 2022;22:299.
    PubMed     Abstract available


  124. ZHANG B, Shi C, Gao Z, Zhong H, et al
    Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
    BMC Cancer. 2022;22:294.
    PubMed     Abstract available


  125. ROJO F, Conde E, Torres H, Cabezon-Gutierrez L, et al
    Clinical and economic impact of 'ROS1-testing' strategy compared to a 'no-ROS1-testing' strategy in advanced NSCLC in Spain.
    BMC Cancer. 2022;22:292.
    PubMed     Abstract available


  126. HESSLER N, Junger ST, Meissner AK, Kocher M, et al
    Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
    BMC Cancer. 2022;22:275.
    PubMed     Abstract available


  127. LIU S, Tian W, Ma Y, Li J, et al
    Serum exosomal proteomics analysis of lung adenocarcinoma to discover new tumor markers.
    BMC Cancer. 2022;22:279.
    PubMed     Abstract available


  128. CARROLL R, Bortolini M, Calleja A, Munro R, et al
    Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
    BMC Cancer. 2022;22:255.
    PubMed     Abstract available


  129. HOLMEN OLOFSSON G, Mikkelsen MK, Ragle AM, Christiansen AB, et al
    High Intensity Aerobic exercise training and Immune cell Mobilization in patients with lung cancer (HI AIM)-a randomized controlled trial.
    BMC Cancer. 2022;22:246.
    PubMed     Abstract available


  130. MIAO H, Ren Q, Li H, Zeng M, et al
    Comprehensive analysis of the autophagy-dependent ferroptosis-related gene FANCD2 in lung adenocarcinoma.
    BMC Cancer. 2022;22:225.
    PubMed     Abstract available


    February 2022
  131. BOGERE N, Bongomin F, Katende A, Omaido BA, et al
    A 10-year retrospective study of lung cancer in Uganda.
    BMC Cancer. 2022;22:204.
    PubMed     Abstract available


  132. ZENG Y, Guo T, Zhou Y, Zhao Y, et al
    Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
    BMC Cancer. 2022;22:198.
    PubMed     Abstract available


  133. WEN S, Peng W, Chen Y, Du X, et al
    Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO.
    BMC Cancer. 2022;22:193.
    PubMed     Abstract available


  134. VIVODA TOMSIC M, Korosec P, Kovac V, Bisdas S, et al
    Dynamic contrast-enhanced MRI in malignant pleural mesothelioma: prediction of outcome based on DCE-MRI measurements in patients undergoing cytotoxic chemotherapy.
    BMC Cancer. 2022;22:191.
    PubMed     Abstract available


  135. XU Y, Lin G, Liu Y, Lin X, et al
    An integrated analysis of the competing endogenous RNA network associated of prognosis of stage I lung adenocarcinoma.
    BMC Cancer. 2022;22:188.
    PubMed     Abstract available


  136. KANEDA T, Kurata T, Yoshida T, Kibata K, et al
    Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer.
    BMC Cancer. 2022;22:154.
    PubMed     Abstract available


  137. SHARMA AL, Meitei PM, Machathoibi TC, Singh NT, et al
    Ovarian cancer G protein-coupled receptor 1 inhibits A549 cells migration through casein kinase 2alpha intronless gene and neutral endopeptidase.
    BMC Cancer. 2022;22:143.
    PubMed     Abstract available


  138. STROYAKOVSKIY DL, Fadeeva NV, Matrosova MP, Shelepen KG, et al
    Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab.
    BMC Cancer. 2022;22:129.
    PubMed     Abstract available


    January 2022
  139. YAO Q, Yu Y, Wang Z, Zhang M, et al
    CANT1 serves as a potential prognostic factor for lung adenocarcinoma and promotes cell proliferation and invasion in vitro.
    BMC Cancer. 2022;22:117.
    PubMed     Abstract available


  140. CHEN W, Guo Z, Wu J, Lin G, et al
    Identification of a ZC3H12D-regulated competing endogenous RNA network for prognosis of lung adenocarcinoma at single-cell level.
    BMC Cancer. 2022;22:115.
    PubMed     Abstract available


  141. XIAN H, Li Y, Zou B, Chen Y, et al
    Identification of TIMELESS and RORA as key clock molecules of non-small cell lung cancer and the comprehensive analysis.
    BMC Cancer. 2022;22:107.
    PubMed     Abstract available


  142. KOU W, Li B, Shi Y, Zhao Y, et al
    High complement protein C1q levels in pulmonary fibrosis and non-small cell lung cancer associated with poor prognosis.
    BMC Cancer. 2022;22:110.
    PubMed     Abstract available


  143. NYEIN AF, Bari S, Hogue S, Zhao Y, et al
    Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer.
    BMC Cancer. 2022;22:101.
    PubMed     Abstract available


  144. THOMPSON NA, Stewart GD, Welsh SJ, Doherty GJ, et al
    The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    BMC Cancer. 2022;22:99.
    PubMed     Abstract available


  145. ZHANG Q, Cai XW, Feng W, Yu W, et al
    Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
    BMC Cancer. 2022;22:96.
    PubMed     Abstract available


  146. RAN H, Ma J, Cai L, Zhou H, et al
    Serum cholinesterase may independently predict prognosis in non-small-cell lung cancer.
    BMC Cancer. 2022;22:93.
    PubMed     Abstract available


  147. TUBIO-PEREZ RA, Torres-Duran M, Garcia-Rodriguez ME, Candal-Pedreira C, et al
    Alpha-1 antitrypsin deficiency and risk of lung cancer in never-smokers: a multicentre case-control study.
    BMC Cancer. 2022;22:81.
    PubMed     Abstract available


  148. TUMINELLO S, Alpert N, Veluswamy RR, Kumar A, et al
    Modulation of chemoimmunotherapy efficacy in non-small cell lung cancer by sex and histology: a real-world, patient-level analysis.
    BMC Cancer. 2022;22:80.
    PubMed     Abstract available


  149. ZHOU Y, Yu T, Zhang Y, Qian L, et al
    Comparison of surgical outcomes and prognosis between wedge resection and simple Segmentectomy for GGO diameter between 2 cm and 3 cm in non-small cell lung cancer: a multicenter and propensity score matching analysis.
    BMC Cancer. 2022;22:71.
    PubMed     Abstract available


  150. SHARP J, Prasad V
    An estimate of rate of deviation from NCCN guideline recommendations for central nervous system imaging in trials forming basis for drug approval in first line advanced non-small cell lung cancer (NSCLC).
    BMC Cancer. 2022;22:70.
    PubMed     Abstract available


  151. WINTHER-LARSEN A, Aggerholm-Pedersen N, Sandfeld-Paulsen B
    Inflammation-scores as prognostic markers of overall survival in lung cancer: a register-based study of 6,210 Danish lung cancer patients.
    BMC Cancer. 2022;22:63.
    PubMed     Abstract available


  152. WESSOLLY M, Stephan-Falkenau S, Streubel A, Wiesweg M, et al
    Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy.
    BMC Cancer. 2022;22:46.
    PubMed     Abstract available


  153. VACHENC S, Gobbo J, Moujarrebe SE, Desmoulins I, et al
    OncoSNIPE(R) Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients.
    BMC Cancer. 2022;22:41.
    PubMed     Abstract available


    December 2021
  154. LIN S, Mo H, Li Y, Guan X, et al
    Clinicopathological characteristics and survival outcomes in patients with synchronous lung metastases upon initial metastatic breast cancer diagnosis in Han population.
    BMC Cancer. 2021;21:1330.
    PubMed     Abstract available


  155. ZHENG Y, Tang L, Liu Z
    Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer.
    BMC Cancer. 2021;21:1322.
    PubMed     Abstract available


  156. SUN CY, Shi JF, Fu WQ, Zhang X, et al
    Catastrophic health expenditure and its determinants in households with lung cancer patients in China: a retrospective cohort study.
    BMC Cancer. 2021;21:1323.
    PubMed     Abstract available


  157. JIANG S, Huang L, Zhen H, Jin P, et al
    Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
    BMC Cancer. 2021;21:1308.
    PubMed     Abstract available


    November 2021
  158. MA HC, Liu YH, Ding KL, Liu YF, et al
    Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials.
    BMC Cancer. 2021;21:1278.
    PubMed     Abstract available


  159. QU J, Wang L, Jiang M, Wei Z, et al
    Survival-associated N(6)-adenosine methyltransferase signatures in lung squamous cell carcinoma and clinical verification.
    BMC Cancer. 2021;21:1265.
    PubMed     Abstract available


  160. CHUANG MC, Yang YH, Hsieh MJ, Lin YC, et al
    The association of aspirin use with overall survival of patients with inoperable non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2021;21:1257.
    PubMed     Abstract available


  161. TREMBECKI L, Sztuder A, Pawlak I, Matkowski R, et al
    Analysis of lung cancer measures of the National Cancer Network pilot study in Poland for potential improvement in the quality of advanced-stage lung cancer therapy.
    BMC Cancer. 2021;21:1252.
    PubMed     Abstract available


  162. MIYAWAKI T, Kenmotsu H, Kodama H, Nishioka N, et al
    Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2021;21:1247.
    PubMed     Abstract available


  163. TAKANASHI Y, Funai K, Eto F, Mizuno K, et al
    Decreased sphingomyelin (t34:1) is a candidate predictor for lung squamous cell carcinoma recurrence after radical surgery: a case-control study.
    BMC Cancer. 2021;21:1232.
    PubMed     Abstract available


  164. CHEN Z, Yang C, Guo Z, Song S, et al
    A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma.
    BMC Cancer. 2021;21:1235.
    PubMed     Abstract available


  165. LI J, Liu W, Dong X, Dai Y, et al
    The construction and analysis of ceRNA network and patterns of immune infiltration in lung adenocarcinoma.
    BMC Cancer. 2021;21:1228.
    PubMed     Abstract available


  166. WANG Q, Wei S, Li S, Yu J, et al
    Comparison of the analgesic effect of ultrasound-guided paravertebral block and ultrasound-guided retrolaminar block in Uniportal video-assisted Thoracoscopic surgery: a prospective, randomized study.
    BMC Cancer. 2021;21:1229.
    PubMed     Abstract available


  167. CHEN YY, Chang SC, Chang CY, Chang CF, et al
    Real-world effectiveness of second-line Afatinib versus chemotherapy for the treatment of advanced lung squamous cell carcinoma in immunotherapy-naive patients.
    BMC Cancer. 2021;21:1225.
    PubMed     Abstract available


  168. PAN H, Pan Z, Guo F, Meng F, et al
    MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer.
    BMC Cancer. 2021;21:1218.
    PubMed     Abstract available


  169. BA H, Liu L, Peng Q, Chen J, et al
    The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2021;21:1220.
    PubMed     Abstract available


  170. WANG Y, Zheng R, Hu P, Zhang Z, et al
    Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M.
    BMC Cancer. 2021;21:1215.
    PubMed     Abstract available


  171. ZHENG Q, Wang Z, Zhang M, Yu Y, et al
    Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation.
    BMC Cancer. 2021;21:1216.
    PubMed     Abstract available


  172. LI J, Lam ASM, Yau STY, Yiu KKL, et al
    Antihypertensive treatments and risks of lung Cancer: a large population-based cohort study in Hong Kong.
    BMC Cancer. 2021;21:1202.
    PubMed     Abstract available


  173. HEMMINKI K, Forsti A, Chen T, Hemminki A, et al
    Incidence, mortality and survival in malignant pleural mesothelioma before and after asbestos in Denmark, Finland, Norway and Sweden.
    BMC Cancer. 2021;21:1189.
    PubMed     Abstract available


    October 2021
  174. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
    Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
    BMC Cancer. 2021;21:1168.
    PubMed     Abstract available


  175. BECA JM, Walsh S, Raza K, Hubay S, et al
    Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
    BMC Cancer. 2021;21:1162.
    PubMed     Abstract available


  176. LIU X, Ji W, Zheng K, Lu J, et al
    The correlation between skeletal muscle index of the L3 vertebral body and malnutrition in patients with advanced lung cancer.
    BMC Cancer. 2021;21:1148.
    PubMed     Abstract available


  177. LUERKEN L, Thurn PL, Zeman F, Stroszczynski C, et al
    Conspicuity of malignant pleural mesothelioma in contrast enhanced MDCT - arterial phase or late phase?
    BMC Cancer. 2021;21:1144.
    PubMed     Abstract available


  178. ZHANG P, Li T, Tao X, Jin X, et al
    HRCT features between lepidic-predominant type and other pathological subtypes in early-stage invasive pulmonary adenocarcinoma appearing as a ground-glass nodule.
    BMC Cancer. 2021;21:1124.
    PubMed     Abstract available


  179. UEDA D, Yamamoto A, Shimazaki A, Walston SL, et al
    Artificial intelligence-supported lung cancer detection by multi-institutional readers with multi-vendor chest radiographs: a retrospective clinical validation study.
    BMC Cancer. 2021;21:1120.
    PubMed     Abstract available


  180. MIYAWAKI T, Kenmotsu H, Harada H, Ohde Y, et al
    Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L).
    BMC Cancer. 2021;21:1121.
    PubMed     Abstract available


  181. MERINO T, Pinto MP, Orellana MP, Martinez G, et al
    Multimodal assessment of acute cardiac toxicity induced by thoracic radiotherapy in cancer patients. Study protocol.
    BMC Cancer. 2021;21:1114.
    PubMed     Abstract available


  182. YANG X, Zhong J, Yu Z, Zhuo M, et al
    Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
    BMC Cancer. 2021;21:1107.
    PubMed     Abstract available


  183. ZHANG Y, Yin X, Wang Q, Song X, et al
    A novel gene expression signature-based on B-cell proportion to predict prognosis of patients with lung adenocarcinoma.
    BMC Cancer. 2021;21:1098.
    PubMed     Abstract available


  184. MA W, Liang J, Mo J, Zhang S, et al
    Butyrophilin-like 9 expression is associated with outcome in lung adenocarcinoma.
    BMC Cancer. 2021;21:1096.
    PubMed     Abstract available


  185. BJAANAES MM, Nilsen G, Halvorsen AR, Russnes HG, et al
    Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors.
    BMC Cancer. 2021;21:1089.
    PubMed     Abstract available


    September 2021
  186. HUANG CC, Lai CY, Tsai CH, Wang JY, et al
    Combined effects of cigarette smoking, DNA methyltransferase 3B genetic polymorphism, and DNA damage on lung cancer.
    BMC Cancer. 2021;21:1066.
    PubMed     Abstract available


  187. KIM HS, Kim HJ, Lee MR, Han I, et al
    EMMPRIN expression is associated with metastatic progression in osteosarcoma.
    BMC Cancer. 2021;21:1059.
    PubMed     Abstract available


  188. CHENG S, Yang L, Dai X, Wang J, et al
    The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
    BMC Cancer. 2021;21:1057.
    PubMed     Abstract available


  189. RODRIGUEZ-ACEVEDO AJ, Chan RJ, Olsen CM, Pandeya N, et al
    Out-of-pocket medical expenses compared across five years for patients with one of five common cancers in Australia.
    BMC Cancer. 2021;21:1055.
    PubMed     Abstract available


  190. NIKSIC M, Redondo-Sanchez D, Chang YL, Rodriguez-Barranco M, et al
    The role of multimorbidity in short-term mortality of lung cancer patients in Spain: a population-based cohort study.
    BMC Cancer. 2021;21:1048.
    PubMed     Abstract available


  191. YANG X, Jin X, Xu R, Yu Z, et al
    ER expression associates with poor prognosis in male lung squamous carcinoma after radical resection.
    BMC Cancer. 2021;21:1043.
    PubMed     Abstract available


  192. AI X, Song Z, Jian H, Zhou Z, et al
    Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
    BMC Cancer. 2021;21:1033.
    PubMed     Abstract available


  193. LIU J, Yin J, Liu Y, Xu Z, et al
    Characteristics of 1270 Chinese sibling pairs with cancer.
    BMC Cancer. 2021;21:1027.
    PubMed     Abstract available


  194. WU LL, Li CW, Lin WK, Qiu LH, et al
    Incidence and survival analyses for occult lung cancer between 2004 and 2015: a population-based study.
    BMC Cancer. 2021;21:1009.
    PubMed     Abstract available


  195. JAKOBSEN E, Olsen KE, Bliddal M, Hornbak M, et al
    Forecasting lung cancer incidence, mortality, and prevalence to year 2030.
    BMC Cancer. 2021;21:985.
    PubMed     Abstract available


  196. NAKANISHI K, Nakamura S, Sugiyama T, Kadomatsu Y, et al
    Diagnostic utility of metabolic parameters on FDG PET/CT for lymph node metastasis in patients with cN2 non-small cell lung cancer.
    BMC Cancer. 2021;21:983.
    PubMed     Abstract available


    August 2021
  197. GUTIERREZ L, Royuela A, Carcereny E, Lopez-Castro R, et al
    Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data.
    BMC Cancer. 2021;21:977.
    PubMed     Abstract available


  198. WANG C, Li J, Zhang Q, Wu J, et al
    The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    BMC Cancer. 2021;21:968.
    PubMed     Abstract available


  199. KHALIL AA, Hau E, Gebski V, Grau C, et al
    Personal innovative approach in radiation therapy of lung cancer- functional lung avoidance SPECT-guided (ASPECT) radiation therapy: a study protocol for phase II randomised double-blind clinical trial.
    BMC Cancer. 2021;21:940.
    PubMed     Abstract available


  200. LIU T, Wang J, Li T, Cui P, et al
    Predicting disease progression in advanced non-small cell lung cancer with circulating neutrophil-derived and platelet-derived microparticles.
    BMC Cancer. 2021;21:939.
    PubMed     Abstract available


  201. ZHOU H, Zheng M, Shi M, Wang J, et al
    Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
    BMC Cancer. 2021;21:938.
    PubMed     Abstract available


  202. ZHANG X, Cao Y, Chen L
    Construction of a prognostic signature of autophagy-related lncRNAs in non-small-cell lung cancer.
    BMC Cancer. 2021;21:921.
    PubMed     Abstract available


  203. FEIL C, Staib F, Berger MR, Stein T, et al
    Sniffer dogs can identify lung cancer patients from breath and urine samples.
    BMC Cancer. 2021;21:917.
    PubMed     Abstract available


  204. CAO L, Jia M, Sun PL, Gao H, et al
    Histopathologic features from preoperative biopsies to predict spread through air spaces in early-stage lung adenocarcinoma: a retrospective study.
    BMC Cancer. 2021;21:913.
    PubMed     Abstract available


  205. MUNOZ-MONTANO W, Muniz-Hernandez S, Aviles-Salas A, Catalan R, et al
    RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin.
    BMC Cancer. 2021;21:892.
    PubMed     Abstract available


  206. WANG S, Yu Y, Xu W, Lv X, et al
    Dynamic nomograms combining N classification with ratio-based nodal classifications to predict long-term survival for patients with lung adenocarcinoma after surgery: a SEER population-based study.
    BMC Cancer. 2021;21:653.
    PubMed     Abstract available


    July 2021
  207. YU W, Ye F, Yuan X, Ma Y, et al
    A phase I/II clinical trial on the efficacy and safety of NKT cells combined with gefitinib for advanced EGFR-mutated non-small-cell lung cancer.
    BMC Cancer. 2021;21:877.
    PubMed     Abstract available


  208. WANG X, Cai J, Zeng Z, Liu A, et al
    Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:873.
    PubMed     Abstract available


  209. WU CE, Chang CF, Huang CY, Yang CT, et al
    Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study.
    BMC Cancer. 2021;21:859.
    PubMed     Abstract available


  210. GAO L, Zhang L
    Construction and comprehensive analysis of a ceRNA network to reveal potential prognostic biomarkers for lung adenocarcinoma.
    BMC Cancer. 2021;21:849.
    PubMed     Abstract available


  211. LAI J, Yang H, Xu T
    Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
    BMC Cancer. 2021;21:848.
    PubMed     Abstract available


  212. TANG Y, Zhang R, Li Y, Xu S, et al
    Genetic polymorphisms and haplotypes of ERCC1 and ERCC2 associated with quality of life, depression, and anxiety status among patients with lung cancer.
    BMC Cancer. 2021;21:842.
    PubMed     Abstract available


  213. LUO H, Zhang Y, Qin G, Jiang B, et al
    LncRNA MCM3AP-AS1 sponges miR-148a to enhance cell invasion and migration in small cell lung cancer.
    BMC Cancer. 2021;21:820.
    PubMed     Abstract available


  214. HUNG A, Lee KM, Lynch JA, Li Y, et al
    Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer.
    BMC Cancer. 2021;21:824.
    PubMed     Abstract available


  215. SHEN H, Deng G, Chen Q, Qian J, et al
    The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
    BMC Cancer. 2021;21:825.
    PubMed     Abstract available


  216. CHAU J, Yadav M, Liu B, Furqan M, et al
    Prospective correlation between the patient microbiome with response to and development of immune-mediated adverse effects to immunotherapy in lung cancer.
    BMC Cancer. 2021;21:808.
    PubMed     Abstract available


  217. PARK K, Kim JS, Kim JH, Kim YC, et al
    An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2021;21:802.
    PubMed     Abstract available


  218. PASCOE J, Jackson A, Gaskell C, Gaunt C, et al
    Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH).
    BMC Cancer. 2021;21:800.
    PubMed     Abstract available


  219. WANG X, Zhou B, Xia Y, Zuo J, et al
    A methylation-based nomogram for predicting survival in patients with lung adenocarcinoma.
    BMC Cancer. 2021;21:801.
    PubMed     Abstract available


  220. CHENG L, Han T, Chen B, Nie K, et al
    TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
    BMC Cancer. 2021;21:794.
    PubMed     Abstract available


  221. LIU T, Luo H, Zhang J, Hu X, et al
    Molecular identification of an immunity- and Ferroptosis-related gene signature in non-small cell lung Cancer.
    BMC Cancer. 2021;21:783.
    PubMed     Abstract available


  222. CHEN Z, Wei J, Li M, Zhao Y, et al
    A circular RNAs dataset landscape reveals potential signatures for the detection and prognosis of early-stage lung adenocarcinoma.
    BMC Cancer. 2021;21:781.
    PubMed     Abstract available


  223. SARACINO L, Bortolotto C, Tomaselli S, Fraolini E, et al
    Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study.
    BMC Cancer. 2021;21:762.
    PubMed     Abstract available


    June 2021
  224. HUANG J, Hu M, Niu H, Wang J, et al
    Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.
    BMC Cancer. 2021;21:750.
    PubMed     Abstract available


  225. YANG X, Zheng Y, Han Z, Zhang X, et al
    Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.
    BMC Cancer. 2021;21:752.
    PubMed     Abstract available


  226. CHRISTOPOULOS P, Bozorgmehr F, Bruckner L, Chung I, et al
    Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
    BMC Cancer. 2021;21:743.
    PubMed     Abstract available


  227. CHEN J, Mao J, Ma N, Wu KL, et al
    Definitive carbon ion radiotherapy for tracheobronchial adenoid cystic carcinoma: a preliminary report.
    BMC Cancer. 2021;21:734.
    PubMed     Abstract available


  228. JANG YJ, Hyun DG, Choi CM, Lee DH, et al
    Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung.
    BMC Cancer. 2021;21:731.
    PubMed     Abstract available


  229. RUSMAULLY J, Tvardik N, Martin D, Billmann R, et al
    Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study).
    BMC Cancer. 2021;21:711.
    PubMed     Abstract available


  230. ZENG H, Yang Z, Li J, Wen Y, et al
    Associations between female lung cancer risk and sex steroid hormones: a systematic review and meta-analysis of the worldwide epidemiological evidence on endogenous and exogenous sex steroid hormones.
    BMC Cancer. 2021;21:690.
    PubMed     Abstract available


  231. NADAL E, Bautista D, Cabezon-Gutierrez L, Ortega AL, et al
    Clinical and economic impact of current ALK rearrangement testing in Spain compared with a hypothetical no-testing scenario.
    BMC Cancer. 2021;21:689.
    PubMed     Abstract available


  232. ZHOU H, Li J, Chen Z, Chen Y, et al
    Nitric oxide in occurrence, progress and therapy of lung Cancer: a systemic review and meta-analysis.
    BMC Cancer. 2021;21:678.
    PubMed     Abstract available


  233. CHEN C, Wu Z, Wu Z, Wu C, et al
    Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
    BMC Cancer. 2021;21:666.
    PubMed     Abstract available


    May 2021
  234. HUANG A, Xu Y, Zang X, Wu C, et al
    Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    BMC Cancer. 2021;21:634.
    PubMed     Abstract available


  235. SHAN Q, Shi J, Wang X, Guo J, et al
    A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
    BMC Cancer. 2021;21:640.
    PubMed     Abstract available


  236. SHARMA V, Sharma A, Raina V, Dabkara D, et al
    Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center.
    BMC Cancer. 2021;21:630.
    PubMed     Abstract available


  237. HUANG G, Zhang J, Gong L, Huang Y, et al
    A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
    BMC Cancer. 2021;21:626.
    PubMed     Abstract available


  238. GUO X, Ma W, Wu H, Xu Y, et al
    Synchronous bone metastasis in lung cancer: retrospective study of a single center of 15,716 patients from Tianjin, China.
    BMC Cancer. 2021;21:613.
    PubMed     Abstract available


  239. LU M, Fan X, Liao W, Li Y, et al
    Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis.
    BMC Cancer. 2021;21:616.
    PubMed     Abstract available


  240. CHEN C, Tang Y, Qu WD, Han X, et al
    Evaluation of clinical value and potential mechanism of MTFR2 in lung adenocarcinoma via bioinformatics.
    BMC Cancer. 2021;21:619.
    PubMed     Abstract available


  241. WANG Q, Gao W, Gao F, Jin S, et al
    Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting.
    BMC Cancer. 2021;21:602.
    PubMed     Abstract available


  242. WANG B, Wang S, Ren W
    Development and validation of a nomogram to predict survival outcome among epithelial ovarian cancer patients with site-distant metastases: a population-based study.
    BMC Cancer. 2021;21:609.
    PubMed     Abstract available


  243. HEMMINKI K, Forsti A, Hemminki A, Ljungberg B, et al
    Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor.
    BMC Cancer. 2021;21:604.
    PubMed     Abstract available


  244. MATSUMOTO A, Nakashima C, Kimura S, Sueoka E, et al
    ALDH2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
    BMC Cancer. 2021;21:584.
    PubMed     Abstract available


  245. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Correction to: Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:574.
    PubMed    


  246. GO SI, Park MJ, Lee GW
    Clinical significance of the cachexia index in patients with small cell lung cancer.
    BMC Cancer. 2021;21:563.
    PubMed     Abstract available


  247. ZHU D, Ding R, Ma Y, Chen Z, et al
    Comorbidity in lung cancer patients and its association with hospital readmission and fatality in China.
    BMC Cancer. 2021;21:557.
    PubMed     Abstract available


  248. GARGIULO P, Arenare L, Gridelli C, Morabito A, et al
    Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.
    BMC Cancer. 2021;21:549.
    PubMed     Abstract available


  249. LEVITSKY A, Bernhardson BM, Henoch I, Olin M, et al
    Using patients' own knowledge of early sensations and symptoms to develop an interactive, individualized e-questionnaire to facilitate early diagnosis of lung cancer.
    BMC Cancer. 2021;21:544.
    PubMed     Abstract available


  250. YIN P, Yue B, Zhang J, Liu D, et al
    Optimal margins for early stage peripheral lung adenocarcinoma resection.
    BMC Cancer. 2021;21:533.
    PubMed     Abstract available


  251. JARRY U, Bostoen M, Pineau R, Chaillot L, et al
    Orthotopic model of lung cancer: isolation of bone micro-metastases after tumor escape from Osimertinib treatment.
    BMC Cancer. 2021;21:530.
    PubMed     Abstract available


  252. LESTER J, Escriu C, Khan S, Hudson E, et al
    Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.
    BMC Cancer. 2021;21:515.
    PubMed     Abstract available


  253. ZHU L, Zou C, Zhang Z, Wang J, et al
    Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.
    BMC Cancer. 2021;21:511.
    PubMed     Abstract available


  254. OKUMURA N, Soh J, Suzuki H, Nakata M, et al
    Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301.
    BMC Cancer. 2021;21:506.
    PubMed     Abstract available


  255. ZUO T, Lin W, Liu F, Xu J, et al
    Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum.
    BMC Cancer. 2021;21:505.
    PubMed     Abstract available


  256. MA J, Li X, Zhao S, Wang J, et al
    Robot-assisted thoracic surgery versus video-assisted thoracic surgery for lung lobectomy or segmentectomy in patients with non-small cell lung cancer: a meta-analysis.
    BMC Cancer. 2021;21:498.
    PubMed     Abstract available


  257. WANG C, Hu K, Deng L, He W, et al
    Increased risk of breast cancer-specific mortality among cancer survivors who developed breast cancer as a second malignancy.
    BMC Cancer. 2021;21:491.
    PubMed     Abstract available


  258. CHEN YC, Tsai MJ, Lee MH, Kuo CY, et al
    Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.
    BMC Cancer. 2021;21:495.
    PubMed     Abstract available


  259. KRIEGSMANN K, Zgorzelski C, Muley T, Christopoulos P, et al
    Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples.
    BMC Cancer. 2021;21:486.
    PubMed     Abstract available


    April 2021
  260. WANG X, Zeng Z, Cai J, Xu P, et al
    Efficacy and acquired resistance for EGFR-TKI plus thoracic SBRT in patients with advanced EGFR-mutant non-small-cell lung cancer: a propensity-matched retrospective study.
    BMC Cancer. 2021;21:482.
    PubMed     Abstract available


  261. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
    New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
    BMC Cancer. 2021;21:476.
    PubMed     Abstract available


  262. KAWAGUCHI Y, Hanaoka J, Ohshio Y, Okamoto K, et al
    Locoregional recurrence via mucus-mediated extension following lung resection for mucinous tumors.
    BMC Cancer. 2021;21:470.
    PubMed     Abstract available


  263. YU Y, Ren K
    Five long non-coding RNAs establish a prognostic nomogram and construct a competing endogenous RNA network in the progression of non-small cell lung cancer.
    BMC Cancer. 2021;21:457.
    PubMed     Abstract available


  264. HU J, Chen Y, Zhu X, Ma Q, et al
    Surgical choice of non-small cell lung cancer with unexpected pleural dissemination intraoperatively.
    BMC Cancer. 2021;21:445.
    PubMed     Abstract available


  265. AYERS KL, Ma M, Debussche G, Corrigan D, et al
    A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
    BMC Cancer. 2021;21:441.
    PubMed     Abstract available


  266. HUANG LT, Cao R, Wang YR, Sun L, et al
    Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of ran
    BMC Cancer. 2021;21:426.
    PubMed     Abstract available


  267. ZHANG Y, Simoff MJ, Ost D, Wagner OJ, et al
    Understanding the patient journey to diagnosis of lung cancer.
    BMC Cancer. 2021;21:402.
    PubMed     Abstract available


  268. JOHNSON MK, Wu S, Pankratz DG, Fedorowicz G, et al
    Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules.
    BMC Cancer. 2021;21:400.
    PubMed     Abstract available


  269. STORK T, Boemans R, Hardes J, Streitburger A, et al
    Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.
    BMC Cancer. 2021;21:375.
    PubMed     Abstract available


  270. HUANG YS, Chen JL, Chen HM, Yeh LH, et al
    Assessing tumor angiogenesis using dynamic contrast-enhanced integrated magnetic resonance-positron emission tomography in patients with non-small-cell lung cancer.
    BMC Cancer. 2021;21:348.
    PubMed     Abstract available


  271. HOSOYA K, Fujimoto D, Morimoto T, Kumagai T, et al
    Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study.
    BMC Cancer. 2021;21:346.
    PubMed     Abstract available


  272. BADE BC, Gan G, Li F, Lu L, et al
    "Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study".
    BMC Cancer. 2021;21:352.
    PubMed     Abstract available


    March 2021
  273. MIYANAGA A, Matsumoto M, Beck JA, Horikawa I, et al
    EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells.
    BMC Cancer. 2021;21:310.
    PubMed     Abstract available


  274. SATO A, Matsubayashi K, Morishima T, Nakata K, et al
    Increasing trends in the prevalence of prior cancer in newly diagnosed lung, stomach, colorectal, breast, cervical, and corpus uterine cancer patients: a population-based study.
    BMC Cancer. 2021;21:264.
    PubMed     Abstract available


  275. XING W, Sun H, Yan C, Zhao C, et al
    A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules.
    BMC Cancer. 2021;21:263.
    PubMed     Abstract available


  276. ZHAO Y, Gao Y, Xu X, Zhou J, et al
    Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
    BMC Cancer. 2021;21:257.
    PubMed     Abstract available


  277. LI Y, Zhao X, Xiao H, Yang B, et al
    APE1 may influence CD4+ naive T cells on recurrence free survival in early stage NSCLC.
    BMC Cancer. 2021;21:233.
    PubMed     Abstract available


  278. WONG SK, Hamm J, Shokoohi A, McGahan CE, et al
    Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment.
    BMC Cancer. 2021;21:215.
    PubMed     Abstract available


  279. ZHAI Y, Zhao B, Wang Y, Li L, et al
    Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.
    BMC Cancer. 2021;21:213.
    PubMed     Abstract available


    February 2021
  280. ZHU D, Cao D, Shen M, Lv J, et al
    Morphological and genetic heterogeneity of synchronous multifocal lung adenocarcinoma in a Chinese cohort.
    BMC Cancer. 2021;21:176.
    PubMed     Abstract available


  281. WANG Y, Liu J, Huang C, Zeng Y, et al
    Development and validation of a nomogram for predicting survival of pulmonary invasive mucinous adenocarcinoma based on surveillance, epidemiology, and end results (SEER) database.
    BMC Cancer. 2021;21:148.
    PubMed     Abstract available


  282. HE Y, Zhao F, Han Q, Zhou Y, et al
    Prognostic nomogram for predicting long-term cancer-specific survival in patients with lung carcinoid tumors.
    BMC Cancer. 2021;21:141.
    PubMed     Abstract available


  283. HE X, You J, Ding H, Zhang Z, et al
    Vasculogenic mimicry, a negative indicator for progression free survival of lung adenocarcinoma irrespective of first line treatment and epithelial growth factor receptor mutation status.
    BMC Cancer. 2021;21:132.
    PubMed     Abstract available


  284. YANG K, Wu Y
    A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
    BMC Cancer. 2021;21:128.
    PubMed     Abstract available


    January 2021
  285. LI XS, Nie KC, Zheng ZH, Zhou RS, et al
    Molecular subtypes based on DNA methylation predict prognosis in lung squamous cell carcinoma.
    BMC Cancer. 2021;21:96.
    PubMed     Abstract available


  286. OYA Y, Yoshida T, Asada K, Oguri T, et al
    Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
    BMC Cancer. 2021;21:57.
    PubMed     Abstract available


  287. PARK S, Lee SY, Kim D, Sim YS, et al
    Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
    BMC Cancer. 2021;21:52.
    PubMed     Abstract available


    December 2020
  288. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
    Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
    BMC Cancer. 2020;20:1210.
    PubMed     Abstract available


    November 2020
  289. KIM MY, Shin JY, Kim JO, Son KH, et al
    Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma.
    BMC Cancer. 2020;20:1057.
    PubMed     Abstract available


    October 2020
  290. WANG B, Xu L, Li Q, Man S, et al
    Endostar continuous versus intermittent intravenous infusion combined with chemotherapy for advanced NSCLC: a systematic review and meta-analysis including non-randomized studies.
    BMC Cancer. 2020;20:1021.
    PubMed     Abstract available


  291. YAMAMOTO T, Niibe Y, Aoki M, Shintani T, et al
    Analyses of the local control of pulmonary Oligometastases after stereotactic body radiotherapy and the impact of local control on survival.
    BMC Cancer. 2020;20:997.
    PubMed     Abstract available


    September 2020
  292. BILGUUN EO, Kaira K, Kawabata-Iwakawa R, Rokudai S, et al
    Distinctive roles of syntaxin binding protein 4 and its action target, TP63, in lung squamous cell carcinoma: a theranostic study for the precision medicine.
    BMC Cancer. 2020;20:935.
    PubMed     Abstract available


  293. SHINODA Y, Kobayashi E, Kobayashi H, Mori T, et al
    Prognostic factors of metastatic myxoid liposarcoma.
    BMC Cancer. 2020;20:883.
    PubMed     Abstract available


  294. ARRIETA O, Catalan R, Guzman-Vazquez S, Barron F, et al
    Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
    BMC Cancer. 2020;20:829.
    PubMed     Abstract available


    August 2020
  295. SAURABH K, Shah PP, Doll MA, Siskind LJ, et al
    UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
    BMC Cancer. 2020;20:824.
    PubMed     Abstract available


  296. BU X, Liu J, Wei L, Wang X, et al
    Epidemiological features and survival outcomes in patients with malignant pulmonary blastoma: a US population-based analysis.
    BMC Cancer. 2020;20:811.
    PubMed     Abstract available


  297. DUAN H, Liang L, Xie S, Wang C, et al
    The impact of order with radiation therapy in stage IIIA pathologic N2 NSCLC patients: a population-based study.
    BMC Cancer. 2020;20:809.
    PubMed     Abstract available


  298. BOZORGMEHR F, Chung I, Christopoulos P, Krisam J, et al
    Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    BMC Cancer. 2020;20:806.
    PubMed     Abstract available


  299. LIANG J, Li J, Li Z, Meng T, et al
    Differentiating the lung lesions using Intravoxel incoherent motion diffusion-weighted imaging: a meta-analysis.
    BMC Cancer. 2020;20:799.
    PubMed     Abstract available


  300. TAKANASHI Y, Funai K, Sato S, Kawase A, et al
    Sphingomyelin(d35:1) as a novel predictor for lung adenocarcinoma recurrence after a radical surgery: a case-control study.
    BMC Cancer. 2020;20:800.
    PubMed     Abstract available


  301. JIANG H, Xu S, Chen C
    A ten-gene signature-based risk assessment model predicts the prognosis of lung adenocarcinoma.
    BMC Cancer. 2020;20:782.
    PubMed     Abstract available


  302. ZHONG L, Xie L, Yang Z, Li L, et al
    Prognostic value of S1PR1 and its correlation with immune infiltrates in breast and lung cancers.
    BMC Cancer. 2020;20:766.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: